Highlights

  • FY2026 Revenue reached A$10.867 billion, up 13%, including 5% organic growth.
  • Underlying EBITDA increased 11% to A$1.933 billion, while underlying net profit rose 17% to A$621 million.
  • Germany delivered 43% statutory revenue growth and 5% organic growth, supported by the LADR Acquisition and advanced diagnostics.
  • Switzerland recorded 4% organic growth in constant currency, with integration synergies supporting Margin improvement.
  • Sonic commenced digital and AI transformation initiatives while continuing integration and productivity programs across its global laboratory network.

Sonic Healthcare Limited (ASX: SHL) is a global provider of medical diagnostic services, including pathology, clinical laboratory and radiology services for clinicians, hospitals, community health services and patients. Its FY2026 results showed higher revenue and Earnings across the group, with organic growth, acquisition integration and operational initiatives contributing to performance in Europe and other major markets.

FY2026 Earnings Reflect Broader Diagnostic Activity

For the year ended 30 June 2026, Sonic reported revenue of A$10.867 billion, an increase of 13%. Underlying EBITDA rose 11% to A$1.933 billion and underlying net profit increased 17% to A$621 million. Organic revenue growth was 5%, reflecting Demand across the group’s established diagnostic operations as well as contribution from recently acquired businesses. The company also maintained its progressive Dividend approach, with total dividends for the year of A$1.08 per share.

Germany Integration Advances Across the Laboratory Network

Germany was a major contributor to FY2026 growth. Statutory revenue increased 43%, while organic growth was 5%. Sonic said the integration of the LADR Laboratory Group progressed during the year, with work spanning laboratory operations, sales, logistics, technical maintenance, information technology and financial systems. The group also completed major laboratory infrastructure projects and continued initiatives aimed at consolidating operations and capturing further efficiencies.

Switzerland Delivers Growth and Integration Synergies

Sonic’s Swiss operations recorded organic growth of 4% in constant currency, accelerating to 6% in the second half. The company attributed margin improvement to synergies from the integration of the SYNLAB Suisse and Dr Risch acquisitions. Four laboratory mergers were completed in Geneva, Lausanne, Zurich and Ticino, while additional optimisation work continued across procurement, logistics, sales, information technology and external reference testing.

Digital and Operational Programs Remain in Focus

Across the wider group, Sonic commenced digital and AI transformation initiatives during FY2026. The company also continued operational improvement programs intended to simplify laboratory processes, improve productivity and support service delivery. These initiatives sit alongside Investment in advanced diagnostics, which the company identified as one of the contributors to organic growth during the year.

Key Insights

Sonic Healthcare’s FY2026 performance was shaped by a combination of organic diagnostic demand, integration of acquired laboratory businesses and group-wide productivity initiatives. Germany and Switzerland remained important areas of operational activity, while digital and AI programs added another element to the company’s efficiency agenda. Future reporting will show how these integration and transformation initiatives progress across the broader diagnostics network.